Ignite Creation Date:
2024-05-06 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 2:18 PM
Study NCT ID:
NCT05123365
Status:
RECRUITING
Last Update Posted:
2024-01-18
First Post:
2021-11-05
Brief Title:
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
Sponsor:
University of California Irvine
Organization:
University of California Irvine
Study Overview
Official Title:
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase III study evaluating the optimal dose of N-acetylcysteine N-AC in patients with myeloproliferative neoplasms MPN
Detailed Description:
This is a phase III open-label clinical trial determining the optimal biological dose OBD of N-acetylcysteine in subjects with myeloproliferative neoplasms These are subjects who have a diagnosis of essential thrombocythemia ET polycythemia vera PV or myelofibrosis MF
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UCI 20-50 | OTHER | CFCCC | None |